Literature DB >> 22865237

Antidepressant use is related to larger white matter lesion volume in patients with symptomatic atherosclerotic disease: the SMART-MR study.

Anne M Grool1, Yolanda van der Graaf, Koen L Vincken, Theo D Witkamp, Willem P Th M Mali, Mirjam I Geerlings.   

Abstract

Although a relation between depression and white matter lesions (WML) is frequently observed, the direction of causation remains unknown. We investigated whether depressed mood was associated with baseline severity and change in WML volume during 4 years of follow-up, and the relative contribution of mood symptoms and antidepressant use to this relation. Within the SMART-MR study 594 patients (58 ± 10 years) with symptomatic atherosclerotic disease had assessments of mood symptoms and antidepressant use and 1.5 T MRI at baseline and after 3.9 ± 0.4 years of follow-up. Mood symptoms were assessed using the Mental Health Index (MHI-5). Depressed mood was defined as antidepressant use and/or MHI-5 score ≤ 52. Volumetric WML measures (deep and periventricular) were obtained with automated segmentation. Linear regression analyses were adjusted for age, sex, baseline WML volume, follow-up time, vascular risk factors and infarcts. Depressed mood was not associated with larger WML volume at baseline. However, when separate contributions were distinguished, antidepressant use was associated with greater deep (B = 0.50 mL, 95 % CI 0.04-0.96) and periventricular WML volume (B = 0.47 mL, 95 % CI 0.05-0.89) at baseline, while mood symptoms were not. Antidepressants were associated with a modest but non-significant increase in progression of periventricular WML volume over 4 years of follow-up (B = 0.21 mL, 95 % CI -0.05 to 0.47). WML at baseline were not associated with new-onset depressed mood at follow-up. Antidepressants, but not mood symptoms, were associated with greater WML volume and a modest, although non-significant increase in periventricular WML volume in patients with symptomatic atherosclerotic disease. Future studies are needed to determine whether this may be a direct effect, or whether other underlying diseases for which antidepressants are prescribed influence this relation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865237     DOI: 10.1007/s00415-012-6616-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  47 in total

1.  Depression and incident stroke in women.

Authors:  An Pan; Olivia I Okereke; Qi Sun; Giancarlo Logroscino; JoAnn E Manson; Walter C Willett; Alberto Ascherio; Frank B Hu; Kathryn M Rexrode
Journal:  Stroke       Date:  2011-08-11       Impact factor: 7.914

2.  Measuring longitudinal white matter changes: comparison of a visual rating scale with a volumetric measurement.

Authors:  D M J van den Heuvel; V H ten Dam; A J M de Craen; F Admiraal-Behloul; A C G M van Es; W M Palm; A Spilt; E L E M Bollen; G J Blauw; L Launer; R G J Westendorp; M A van Buchem
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

Review 3.  Pathophysiology of age-related cerebral white matter changes.

Authors:  Leonardo Pantoni
Journal:  Cerebrovasc Dis       Date:  2002       Impact factor: 2.762

4.  Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies.

Authors:  Amanda Nicholson; Hannah Kuper; Harry Hemingway
Journal:  Eur Heart J       Date:  2006-11-02       Impact factor: 29.983

5.  Frequency of depression after stroke: a systematic review of observational studies.

Authors:  Maree L Hackett; Chaturangi Yapa; Varsha Parag; Craig S Anderson
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

6.  Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study.

Authors:  Jordan W Smoller; Matthew Allison; Barbara B Cochrane; J David Curb; Roy H Perlis; Jennifer G Robinson; Milagros C Rosal; Nanette K Wenger; Sylvia Wassertheil-Smoller
Journal:  Arch Intern Med       Date:  2009-12-14

7.  Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease: The PROSPER Study.

Authors:  C E Versluis; R C van der Mast; M A van Buchem; E L E M Bollen; G J Blauw; J A H Eekhof; N J A van der Wee; A J M de Craen
Journal:  Int J Geriatr Psychiatry       Date:  2006-04       Impact factor: 3.485

8.  Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study.

Authors:  Mirjam I Geerlings; Auke P A Appelman; Koen L Vincken; Ale Algra; Theo D Witkamp; Willem P T M Mali; Yolanda van der Graaf
Journal:  Atherosclerosis       Date:  2009-11-10       Impact factor: 5.162

9.  Regional white matter pathology in mild cognitive impairment: differential influence of lesion type on neuropsychological functioning.

Authors:  Lisa Delano-Wood; Norm Abeles; Joshua M Sacco; Christina E Wierenga; Nikki R Horne; Andrea Bozoki
Journal:  Stroke       Date:  2008-02-07       Impact factor: 7.914

10.  Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study.

Authors:  William Whang; Laura D Kubzansky; Ichiro Kawachi; Kathryn M Rexrode; Candyce H Kroenke; Robert J Glynn; Hasan Garan; Christine M Albert
Journal:  J Am Coll Cardiol       Date:  2009-03-17       Impact factor: 27.203

View more
  2 in total

1.  White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression.

Authors:  Alexander Khalaf; Kathryn Edelman; Dana Tudorascu; Carmen Andreescu; Charles F Reynolds; Howard Aizenstein
Journal:  Neuropsychopharmacology       Date:  2015-06-10       Impact factor: 7.853

2.  Depression in small-vessel disease relates to white matter ultrastructural damage, not disability.

Authors:  Rebecca L Brookes; Vanessa Herbert; Andrew J Lawrence; Robin G Morris; Hugh S Markus
Journal:  Neurology       Date:  2014-09-17       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.